This is the authors' abstract. We don't add key points for this paper.
This pipeline analysis shows that target biological processes are more diversified, biomarkers are more regularly used, and repurposed agents are being explored to determine their utility for the treatment of AD.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Cummings et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: